ImmuPharma PLC

("ImmuPharma" or the "Company")

AIM Rule 17 Notice

ImmuPharma PLC (LSE: IMM), specialist drug discovery and development company, announces pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules"), the following director's disclosure under Schedule Two, Paragraph (g) of the AIM Rules:

Tim McCarthy, the Company's Non-executive Chairman, is currently on the board of Harvard Healthcare Limited ("Harvard"). On 5 March 2018 the Directors of Harvard passed a board resolution following which Harvard will be placed into a Creditors' Voluntary Liquidation.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

-Ends-